Exousia Pro, Inc. Completes Exclusive Licensing Agreement With the University of Central Florida for Novel Cancer Diagnostic and Therapy Platforms

Rhea-AI Summary

Exousia Pro (OTCID:LMMY) executed an exclusive, worldwide license with the University of Central Florida for patented and patent-pending exosome technologies for cancer diagnosis and therapy.

Key assets include a U.S. patent (US011193174B2, granted Dec 7, 2021) for Exosomal NANOG DNA as a diagnostic marker, and a patent-pending exosomal delivery platform with filings in the U.S., Canada, China, Europe, and Japan. The licensed diagnostic aims to be a non-invasive, single multi-cancer screening using 2 ml saliva and PCR processing to detect rare, late-presenting “silent killer” cancers. Exousia Pro plans two subsidiaries: Exousia Health to commercialize the NANOG screening test and a majority-owned sub-licensee to operate as Exousia Bio (OTCID:LMMY) for therapy applications.

Positive

• Exclusive worldwide license to UCF exosome IP including US patent US011193174B2
• Diagnostic requires only 2 ml saliva using PCR for rapid, non-invasive screening
• Patent filings pending in U.S., Canada, China, Europe, and Japan

Negative

• Therapeutic platform remains patent-pending in key jurisdictions (not yet granted)
• No clinical performance or validation data for the NANOG screening test disclosed

News Market Reaction

+3.64%

1 alert

+3.64% News Effect

On the day this news was published, LMMY gained 3.64%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Patent grant date: December 7, 2021 Saliva sample volume: 2 ml Negotiation period: 11 months +1 more

4 metrics

Patent grant date December 7, 2021 US011193174B2 for Exosomal NANOG DNA diagnostic marker

Saliva sample volume 2 ml Sample required for NANOG DNA cancer screening test

Negotiation period 11 months Time to execute exclusive license with University of Central Florida

Patent jurisdictions 5 regions Patent applications in U.S., Canada, China, Europe, Japan

Market Reality Check

Price: $0.3859 Vol: Volume 2,851 is below the...

low vol

$0.3859 Last Close

Volume Volume 2,851 is below the 20-day average of 6,905, indicating subdued trading interest pre‑news. low

Technical Price at 0.40 is trading below the 200-day MA of 2.91, reflecting a longer-term downtrend.

Peers on Argus

The stock gained 3.9% while sector peers were mostly flat; only ASPU rose meanin...

The stock gained 3.9% while sector peers were mostly flat; only ASPU rose meaningfully at 14.29%. With no peers in the momentum scanner, the move appeared stock-specific rather than a broad sector rotation.

Historical Context

4 past events · Latest: Dec 04 (Positive)

Pattern 4 events

Date	Event	Sentiment	Move	Catalyst
Dec 04	Expert interview	Positive	+4.8%	Interview with veteran immunologist backing exosome-based cancer therapies.
Dec 02	Licensing deal	Positive	+3.6%	Exclusive worldwide license for exosome cancer diagnostic and therapy IP.
Dec 02	Acquisition/ODD	Positive	+3.6%	All-stock acquisition of Exousia AI and glioblastoma Orphan Drug Designation.
Nov 17	Change of control	Positive	+105.4%	MAJI becomes controlling shareholder via stock exchange and tech licensing.

Pattern Detected

Recent exosome-focused acquisitions, licensing deals, and expert visibility have all been followed by positive price reactions, including a triple-digit move on the November change-of-control transaction.

Recent Company History

This announcement extends a rapid strategic shift toward exosome-based oncology. On Nov 17, 2025, LMMY completed an all-stock acquisition of Exousia AI, triggering a change of control and a 105.4% price jump, and later reported Orphan Drug Designation and detailed share structure metrics. On Dec 2, 2025, the company highlighted the exclusive UCF license for exosomal diagnostics and therapy, which also drew a positive reaction. A subsequent interview with Dr. Marvin Hausman on Dec 4, 2025 reinforced the cancer-therapy focus with another gain.

Market Pulse Summary

This announcement expands LMMY’s transformation into an exosome-focused oncology platform by securin...

Analysis

This announcement expands LMMY’s transformation into an exosome-focused oncology platform by securing an exclusive UCF license for a NANOG DNA saliva-based cancer test and a therapeutic delivery system. It follows recent acquisitions and Orphan Drug Designation that previously coincided with positive price moves. Regulatory filings, however, show no operating revenue, zero assets, and going‑concern warnings. Key factors to watch include progress on subsidiary formation, validation of the diagnostic assay, and concrete financing or partnership milestones.

Key Terms

exosomes, exosomal, biomarker, liquid biopsy, +4 more

8 terms

exosomes medical

"focused on advanced exosome-based delivery systems, today announced"

Exosomes are tiny particles released by cells that carry proteins, genetic material, and other molecules from one cell to another. They act like biological messengers, helping cells communicate and coordinate their activities. For investors, understanding exosomes is important because they are being explored as potential tools for disease diagnosis and treatment, which could influence healthcare markets and innovation.

exosomal medical

"Exosomal NANOG DNA as a Diagnostic Cancer Marker: This key technology"

Describing something derived from or related to exosomes — tiny packets cells naturally release to send signals and carry molecules like proteins, RNA or lipids to other cells. For investors, “exosomal” flags technologies or products that use these biological packets for diagnostics, drug delivery or disease monitoring, which can promise more precise tests or therapies but also face scientific, manufacturing and regulatory hurdles. Think of exosomes as biological mail carriers and “exosomal” as anything that uses or studies that mail.

biomarker medical

"measures Exosomal NANOG DNA, a potent biomarker, and is not influenced"

A biomarker is a measurable indicator found in the body, such as in blood or tissues, that provides information about health, disease, or how the body responds to treatment. For investors, biomarkers can signal the potential success or risk of medical products or therapies, influencing the value of related companies and industry trends. They act like signals or clues that help assess the progress of medical advancements and their market impact.

liquid biopsy medical

"competitive advantages in the field of liquid biopsy:Universal Screening"

A liquid biopsy is a laboratory test that looks for tiny pieces of tumor or disease-related material — such as DNA, proteins, or cells — circulating in blood or other body fluids, allowing detection and monitoring without a surgical tissue sample. For investors, it matters because these tests can speed diagnosis, guide treatment choices, enable easier repeat testing, and create recurring revenue streams if adopted widely, affecting a medical company's growth and regulatory risk profile.

polymerase chain reaction medical

"the test uses Polymerase Chain Reaction (PCR) processing to provide rapid"

A polymerase chain reaction (PCR) is a laboratory method that makes many copies of a tiny piece of genetic material, like using a photocopier to turn one page into thousands so it can be read and analyzed. Investors care because PCR underlies many diagnostic tests, research tools and quality control processes; changes in demand, costs, accuracy or regulation of PCR can affect revenue, competitive positions and the speed at which medical products reach the market.

PCR medical

"uses Polymerase Chain Reaction (PCR) processing to provide rapid"

PCR (polymerase chain reaction) is a laboratory method that makes many copies of a tiny piece of genetic material (DNA or RNA) so scientists can detect and study it reliably — think of photocopying a faint, tiny note until the words are easy to read. For investors, PCR matters because it underpins diagnostic tests, drug development, and biotech tools whose sales, regulatory approvals, and real-world use can materially affect company revenues and market perceptions during health events or product launches.

gene expression modulating agents medical

"delivery of gene expression modulating agents for therapy against cancer"

Gene expression modulating agents are drugs or compounds that change how much a cell turns specific genes on or off, similar to using a dimmer switch to raise or lower a light. They matter to investors because altering gene activity can treat diseases by reducing harmful proteins or boosting helpful ones, offering large commercial potential but also carrying scientific, regulatory and safety risks that affect a drug’s development timeline and investment value.

diagnostic cancer marker medical

"Exosomal NANOG DNA as a Diagnostic Cancer Marker: This key technology"

A diagnostic cancer marker is a measurable biological sign—such as a molecule in blood or tissue—that signals the presence, type, or behavior of a cancer, like a fingerprint or smoke alarm for disease detection. Investors care because these markers drive demand for tests, guide treatment choices, affect regulatory approval and reimbursement, and can create steady revenue streams or boost the value of drugs that depend on the marker for patient selection.

AI-generated analysis. Not financial advice.

ORLANDO, FLORIDA / ACCESS Newswire / December 2, 2025 / Exousia Pro, Inc. (OTCID:MAJI), a clinical-stage biotechnology company focused on advanced exosome-based delivery systems, today announced the execution of an exclusive licensing agreement between its wholly owned subsidiary, Exousia Pro Holding Management, LLC, and the University of Central Florida (UCF) concerning its groundbreaking technology for both the diagnosis and treatment of cancer using exosomes.

Securing Foundational, Worldwide Intellectual Property

The agreement grants Exousia Pro Holding Management (EPHM) an exclusive license to UCF-developed patented and patent-pending intellectual property. This robust intellectual property portfolio includes:

1. Exosomal NANOG DNA as a Diagnostic Cancer Marker: This key technology is protected by a U.S. Patent (US011193174B2) granted on December 7, 2021, focusing on the use of Exosomal NANOG DNA for cancer screening.

2. Exosomal Delivery Platform for Therapy: A comprehensive system for the delivery of gene expression modulating agents for therapy against cancer and viral infection, with patent applications pending across multiple critical jurisdictions, including the U.S., Canada, China, Europe, and Japan.

This exclusive, global licensing strategy ensures Exousia Pro maintains a dominant position over foundational technologies essential for developing next-generation exosome-based diagnostics and therapeutics.

Game-Changing Diagnostic Potential: Detecting Rare Silent Killer Cancers

The licensed technology incorporates the development of a proprietary NANOG DNA cancer screening test. This test is positioned as a game-changing, non-invasive diagnostic tool with the ability to detect a wide spectrum of cancers, including rare, highly aggressive malignancies often referred to as "silent killer" cancers due to their late-stage presentation.

The test offers several competitive advantages in the field of liquid biopsy:

• Universal Screening: The test is designed as a single, multi-cancer screening tool, eliminating the need for separate tests for different cancer types.

• High Sensitivity and Specificity: The assay measures Exosomal NANOG DNA, a potent biomarker, and is not influenced by external factors such as medications or co-existing health ailments, providing exceptional reliability.

• Non-Invasive and Efficient: Requiring only a minimal 2 ml saliva sample, the test uses Polymerase Chain Reaction (PCR) processing to provide rapid, scalable results, lowering barriers to early detection.

Exousia Pro plans to create a new subsidiary, Exousia Health, to manage the commercialization of this crucial cancer screening test under a sub-license agreement with EPHM. Furthermore, a separate sub-license will be granted to its majority-owned subsidiary, LAMY, to become Exousia Bio, Inc. (OTCID:LMMY), for cancer-therapy applications.

Executive Commentary

"The formal execution of this exclusive agreement with the University of Central Florida culminates eleven months of intensive negotiations and represents a major, foundational milestone for the Company," stated Matt Dwyer, President of Exousia Pro, Inc. "This license is absolutely critical to the success of leveraging NANOG in cancer therapy and ensures that we are positioned to benefit from future potential pharmaceutical partnerships. Crucially, it provides us with the rights to a diagnostic tool, the NANOG DNA screening test, and the potential to be the first non-invasive diagnostic capable of detecting rare, silent killer cancers at an early, actionable stage."

About Exousia Pro, Inc.

Exousia Pro, Inc. (EXO), through its subsidiary Exousia Pro Holding Management, is a biotechnology company advancing proprietary technologies. Its focus is on utilizing exosomes for nucleic acid loading and targeted delivery to tissues and cells, alongside developing highly sensitive assays for measuring NANOG DNA as a universal cancer screening test.

SAFE HARBOR

Forward-looking statements in this release are made under the "safe harbor" provision of the Private Securities Litigation Reform Act of 1995. Exousia Pro, Inc.'s forward-looking statements do not guarantee future performance. This news release includes forward-looking statements concerning the parties' future level of business. These statements are necessarily subject to risk and uncertainty. Actual results could differ materially from those projected in these forward-looking statements due to certain risk factors that could cause results to differ materially from estimated results. Management cautions that all statements as to future results of operations are necessarily subject to risks, uncertainties, and events that may be beyond the control of Exousia Pro, Inc., and no assurance can be given that such results will be achieved. Potential risks and uncertainties include, but are not limited to, the ability to procure, appropriately price, retain, and complete projects and changes in products and competition.

CONTACT:

Exousia Pro, Inc.
www.Exousiapro.com
X: @Exousia_Pro

Investor Relations
ir@exousiapro.com

SOURCE: Exousia Pro, Inc.

View the original press release on ACCESS Newswire

FAQ

What did Exousia Pro announce on December 2, 2025 regarding LMMY?

Exousia Pro announced an exclusive, worldwide license from University of Central Florida for exosome-based cancer diagnostic and therapy technologies.

What patent covers Exousia Pro's NANOG cancer diagnostic (LMMY)?

The diagnostic is covered by U.S. patent US011193174B2, granted on December 7, 2021.

How does the Exousia Pro NANOG screening test work and what sample is required?

The test measures Exosomal NANOG DNA from a 2 ml saliva sample and uses PCR for analysis.

Will Exousia Pro commercialize the NANOG test through a new unit?

Yes, the company plans to create Exousia Health to manage commercialization under a sub-license.

Are the therapy delivery patents for LMMY fully granted worldwide?

No; the exosomal delivery platform has patent applications pending across multiple jurisdictions.

Does the press release include clinical validation data for the screening test?

No; the announcement does not disclose clinical performance or validation metrics.